Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel
NASDAQ:MRKR

Marker Therapeutics Q2 2024 Earnings Report

Marker Therapeutics logo
$1.46 +0.02 (+1.39%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 0.00 (0.00%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Marker Therapeutics EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Marker Therapeutics Revenue Results

Actual Revenue
$1.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Marker Therapeutics Announcement Details

Quarter
Q2 2024
Date
8/14/2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Marker Therapeutics' Q1 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Marker Therapeutics' Q2 2024 Press ReleasePress Release
(8-K)
Marker Therapeutics' Q2 2024 Quarterly reportQuarterly report
(10-Q)

Marker Therapeutics Earnings Headlines

Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/marker-therapeutics-mrkr-price-target-decreased-by-12-83-to-8-02/ar-AA20ulsd
Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology
March 18, 2026  |  quiverquant.comQ
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 8 at 1:00 AM  |  Porter & Company (Ad)
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
March 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/18/3258655/0/en/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results.html
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/18/3240173/0/en/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference.html
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/good-morning-america-features-baylor-college-of-medicine-pancreatic-cancer-study-utilizing-marker-therapeutics-mar-t-cell-technology-1035745259
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics (NASDAQ:MRKR) is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers. The company has initiated early-phase clinical studies in patients with HPV16-positive head and neck cancers, as well as exploratory trials in other solid tumor indications. Marker conducts its research and development activities at its headquarters in Houston, Texas, and collaborates with academic and clinical partners across the United States to support trial enrollment and translational research efforts.

Founded in 2019 through a corporate reorganization and public listing, Marker Therapeutics transitioned its focus from earlier-stage RNA-based programs to cell-based immunotherapies. The company is guided by a management team experienced in cell therapy development, process scale-up and regulatory strategy. With an emphasis on personalized medicine, Marker is advancing its pipeline toward later-stage studies and exploring combination approaches alongside established oncology agents.

View Marker Therapeutics Profile
Earnings Tools